Navigation Links
Rigel Announces Third Quarter 2008 Financial Results and Clinical Update
Date:11/3/2008

o Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary.

About Rigel (http://www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

This press release contains "forward-looking" statements, including statements related to relating to the potential efficacy of R788, as well as Rigel's plans to pursue clinical development of R788 and other product candidates, and the timing thereof, the market opportunity for its product candidates, expansion of and changes in its product portfolio and its plans to pursue collaboration partnerships for product candidates. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "plans," "potential," "intends," "indicates," "promising," "expects," "anticipates" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials and the commercialization of product candidates, potential problems that may arise in the clinical testing and approval process and R
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Rigel to Host Update Conference Call
2. Rigel Announces Fourth Quarter and Year End 2007 Financial Results
3. Rigel to Present at BIO CEO & Investor Conference
4. Rigel Announces Pricing of Public Offering of Common Stock
5. Rigel to Present Research Programs at Scientific Conferences
6. Rigel to Present at BIO Investor Forum 2007
7. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
8. VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer
9. OriGene Announces 37,000 ORF cDNA Clones in a GFP Vector
10. Sharps Compliance Corp. Announces Appointment of John R. Grow as President and Chief Operating Officer
11. BMP Sunstone Announces Participation in November Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2014)... PLANTATION, Fla. , July 18, 2014  Neurotrope, ... 2014,  its Board of Directors appointed Co-Chairmen Charles ... Co-Chief Executive Officers on an interim basis, effective immediately. ... , who is no longer Chief Executive Officer of ... or the Company and whose employment agreement with Neurotrope ...
(Date:7/18/2014)... CHICAGO, Ill. , July 18, 2014 ... an infographic highlighting AbbVie and Shire,s complementary ... combination. A copy of the ... website at:  http://www.abbvieinvestor.com/phoenix.zhtml?c=251551&p=irol-disclaimer-documents ... Takeover Code, a copy of this announcement ...
(Date:7/18/2014)... Provia Laboratories announces the addition of Dr. Jim ... Vaught has worked in the field of biorepository and ... of the founding members of ISBER – the International ... he served as its second president, and 15 years ... Vaught began working with the National Institutes of Health ...
(Date:7/17/2014)... Australia , July 17, 2014  Prana Biotechnology ... provided an update on its clinical development program for ... the Florey Institute of Neuroscience and Mental Health, The ... Phase 2 IMAGINE and EURO trials in his presentation ... Copenhagen, Denmark . The presentation is ...
Breaking Biology Technology:Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs 2Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs 3Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs 4NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 2NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 3NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 4NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 5NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 6NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 7Dr. Jim Vaught, Ph.D., Former Chief of BBRB, Joins Provia Laboratories as Advisory Board Member 2Dr. Jim Vaught, Ph.D., Former Chief of BBRB, Joins Provia Laboratories as Advisory Board Member 3Prana Alzheimer's disease Development Program update 2Prana Alzheimer's disease Development Program update 3Prana Alzheimer's disease Development Program update 4Prana Alzheimer's disease Development Program update 5
... Do the principles of quantum mechanics apply to biological ... Institute,s Chemical Physics Department (Faculty of Chemistry), both biologists ... to be like apples and oranges. But research he ... in Science , definitively shows that a biological ...
... China March 31, 2011 /PRNewswire-Asia/ -- Tiens Biotech Group (USA), ... ), a company dedicated to the research, development, ... and dietary supplements, today announced financial results for ... revenue was $41.3 million, compared to $62.0 million for 2009. ...
... March 31, 2011 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: ... developer, manufacturer and distributor of probiotics products in China, ... sales order from its newly signed U.S. customer. ... first sales order, and formally entered into its agreement ...
Cached Biology Technology:Biological molecules select their spin 2Tiens Biotech Group (USA) Reports 2010 Results 2Tiens Biotech Group (USA) Reports 2010 Results 3Tiens Biotech Group (USA) Reports 2010 Results 4Tiens Biotech Group (USA) Reports 2010 Results 5Tiens Biotech Group (USA) Reports 2010 Results 6Tiens Biotech Group (USA) Reports 2010 Results 7China-Biotics Receives First U.S. Sales Order 2China-Biotics Receives First U.S. Sales Order 3
(Date:7/22/2014)... SHELTON, Conn. , July 22, 2014 /PRNewswire/ ... on the growing m-commerce market, announces its next generation ... weekly 30-minute consumer oriented television show that airs ... Network. NewsWatch regularly features top ... on July 31st on the History Channel (6:00-6:30am ...
(Date:7/22/2014)... of immune cell widely believed to exacerbate chronic ... multiple sclerosis (MS), can actually protect the brain ... the progression of neurodegenerative diseases, according to Cleveland ... Nature Communications . , The research team, ... Department of Neurosciences at Cleveland Clinic,s Lerner Research ...
(Date:7/22/2014)... the the genus of planthopper known as Conosimus, which ... recently discovered in the southern part of the Iberian ... of it appears in the open-access Journal of ... new species, Conosimus baenai , has been named ... to the taxonomy of Iberian Hemiptera. , Conosimus ...
Breaking Biology News(10 mins):NXT-ID's Next Generation Wocket Smart Wallet to be Featured on NewsWatch, Airing on History Channel, FYI Network and ION Network 2NXT-ID's Next Generation Wocket Smart Wallet to be Featured on NewsWatch, Airing on History Channel, FYI Network and ION Network 3Cleveland Clinic researchers discover neuroprotective role of immune cell 2
... studies continue to validate the use of probiotics to ... for probiotics indicates that the U.S. healthcare community and ... microorganisms. However, because most probiotics are classified as dietary ... individual needs can be challenging. And, as the ...
... The Seventh Annual Symposium on Predictive Health, to ... on health and the human microbiome. The human microbiome ... and viruses, which reside throughout the body. Study ... attention across the United States, including a major federal ...
... of Atlantic salmon (Salmo salar), which have been ... new challenges in the Gulf of Maine, where ... new predators along altered migration routes are affecting ... in the journal Fisheries Management and Ecology, ...
Cached Biology News:As probiotics use grows for gut health, VSL#3 has designations for specific GI issues 2As probiotics use grows for gut health, VSL#3 has designations for specific GI issues 3Predictive health symposium will focus on human microbiome 2Environmental conditions and predators affect Atlantic salmon survival in the Gulf of Maine 2
...
... catalyzes the formation of phosphodiester bonds in ... with 3' hydroxyl and 5' phosphate termini. ... ligation which can be performed in 5 ... substrates for this enzyme. A T4 ...
Porcine Aortic Endothelial Cells (PAOEC) (>500,000 cells)...
Bovine Endometrium Epithelial Cells (BEnEpC) (>500,000 cells)...
Biology Products: